Pharmaceutical Follow-up of Coronary Heart Disease (CHD) Patients

2014-08-27 03:14:00 | BioPortfolio


It is well known that secondary prevention is very important for patients with established coronary heart disease, it reduces both mortality and morbidity. Pharmacists in Norway are not routinely involved in follow-up of this patient group, but many studies have shown that involvement of a pharmacist have a positive influence in achieving therapy goals for e.g. blood pressure, lipids and blood sugar.

The investigators hypothesis is that follow-up by a clinical pharmacist after hospital discharge will increase adherence to clinical guideline recommendations and increase achievement of specific therapy goals for blood pressure, lipids and glucose in patients with established CHD. The investigators plan to include patients with established CHD, discharged from hospital after admission to the cardiology department.

Patients included (18-80 years) will be randomized to an intervention and a control group. In addition to ordinary health care, the intervention group receives follow-up from a clinical pharmacist during one year with three meeting points, at discharge, after three months and after one year. The control group receives only ordinary health care, but are called in after one year for data collection. Patients living in nursing homes, patients already receiving pharmaceutical follow-up elsewhere and cancer patients are excluded from the study. Only patients living in the area of Tromsoe and nearby is included, as they need to physically see the pharmacist.

The follow-up include medication review and subsequently solving of drug related problems in addition to drug information and monitoring of clinical therapy goals relevant for secondary prevention of CHD.

The main outcome measures is adherence to specified review criteria defined in a medication assessment tool (MAT-CHDsp) based on recommendations from the European Society of Cardiology. Other outcome measures include 1)number of drug related problems identified and solved, 2) hospital admissions, 3)deaths.

Study Design

Allocation: Randomized, Control: Uncontrolled, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research


Coronary Heart Disease


Pharmacist follow-up


Hospital Pharmacy of North Norway Trust




Hospital Pharmacy of North Norway Trust

Results (where available)

View Results


Published on BioPortfolio: 2014-08-27T03:14:00-0400

Clinical Trials [4049 Associated Clinical Trials listed on BioPortfolio]

Pharmacist Follow-up, a Qualitative Study of Patient Experience

A pharmacist follow-up procedure is under development. Patients with coronary heart disease (CHD) is being followed up by a pharmacist for one year with three meetings; at discharge from h...

The Impact of Opioids in Coronary Heart Disease

In this study, the risk of opioid medications on coronary heart disease in adults is investigated. Patients with the necessity of a coronary angiography and control patients with a non-car...

Study of an Intervention to Improve Use of Life-saving Medications for Heart Disease

The purpose of this study is to evaluate the effectiveness of a program to help patients with heart disease stay on their heart medications.

Pharmacist Intervention to Decrease Medication Errors in Heart Disease Patients (The PILL-CVD Study)

Many people who have recently left the hospital have difficulties managing their medications, and medication errors are common. Patients with low health literacy levels may have a particul...

Improving Adherence to Pharmacological Treatment

The overall goal of this study was to implement and evaluate the effects of a systems-based and pharmacist-mediated program designed to improve adherence for patients with known coronary h...

PubMed Articles [21705 Associated PubMed Articles listed on BioPortfolio]

Relationship between hyperuricemia and prognosis in patients with heart failure of coronary heart disease after revascularization.

To explore the effect of hyperuricemia on prognosis in patients with heart failure of coronary heart disease (CHD) after revascularization. A single-center retrospective study of all subjects who und...

Coronary computed tomography angiography for heart team decision-making in multivessel coronary artery disease.

Coronary computed tomography angiography (CTA) has emerged as a non-invasive diagnostic method for patients with suspected coronary artery disease, but its usefulness in patients with complex coronary...

Psychiatric comorbidities in acute coronary syndromes: Six-month follow-up study.

Acute coronary syndrome (ACS) caused by coronary atherosclerosis include ST-segment elevation myocardial infarction (STEMI), non-STEMI, and unstable angina. The relation between psychiatric disorders ...

'Heart disease never entered my head' Women's Understanding of Coronary Heart Disease Risk Factors.

This study investigated experiences of women with a primary diagnosis of ACS (NSTEMI & Unstable Angina). The study explored how women interpreted their risk for Coronary Heart Disease (CHD) and how th...

Self-reported myocardial infarction and fatal coronary heart disease among oil spill workers and community members 5 years after Deepwater Horizon.

Chemical, physical and psychological stressors due to the 2010 Deepwater Horizon oil spill may impact coronary heart disease (CHD) among exposed populations. Using longitudinal information from two in...

Medical and Biotech [MESH] Definitions

Abnormal balloon- or sac-like dilatation in the wall of CORONARY VESSELS. Most coronary aneurysms are due to CORONARY ATHEROSCLEROSIS, and the rest are due to inflammatory diseases, such as KAWASAKI DISEASE.

A disorder of cardiac function caused by insufficient blood flow to the muscle tissue of the heart. The decreased blood flow may be due to narrowing of the coronary arteries (CORONARY ARTERY DISEASE), to obstruction by a thrombus (CORONARY THROMBOSIS), or less commonly, to diffuse narrowing of arterioles and other small vessels within the heart. Severe interruption of the blood supply to the myocardial tissue may result in necrosis of cardiac muscle (MYOCARDIAL INFARCTION).

An imbalance between myocardial functional requirements and the capacity of the CORONARY VESSELS to supply sufficient blood flow. It is a form of MYOCARDIAL ISCHEMIA (insufficient blood supply to the heart muscle) caused by a decreased capacity of the coronary vessels.

A congenital coronary vessel anomaly in which the left main CORONARY ARTERY originates from the PULMONARY ARTERY instead of from AORTA. The congenital heart defect typically results in coronary artery FISTULA; LEFT-SIDED HEART FAILURE and MITRAL VALVE INSUFFICIENCY during the first months of life.

Coronary artery bypass surgery on a beating HEART without a CARDIOPULMONARY BYPASS (diverting the flow of blood from the heart and lungs through an oxygenator).

More From BioPortfolio on "Pharmaceutical Follow-up of Coronary Heart Disease (CHD) Patients"

Quick Search


Relevant Topic

Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...

Searches Linking to this Trial